Conditions: Psoriasis
Keywords: psoriasis, brodalumab (AMG 827)
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 661
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses.

Detailed description:
The purpose of this study is to assess the safety and efficacy of brodalumab taken every two weeks at two different doses in participants with moderate to severe plaque psoriasis. A second purpose of this study is to assess the safety and efficacy when brodalumab is replaced with placebo in some participants compared with the participants who are still receiving the brodalumab.

Arms:
arm 1: Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease. arm 2: Administered by subcutaneous (SC) injection until week 12. At week 12, participants are rerandomized to placebo or continued treatment. Participants are retreated at return of disease. arm 3: Administered by SC injection until week 12. At week 12 particpants are assigned to 210 mg brodalumab.

Interventions: intervention 1: 210 mg brodalumab intervention 2: 140 mg brodalumab intervention 3: placebo
Intervention descriptions: intervention 1: 210 mg brodalumab administered subcutaneous (SC) intervention 2: 140 mg brodalumab administered subcutaneous (SC) intervention 3: Placebo administered subcutaneous (SC)

Protocol document: